Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.3890
Abstract: This cohort study investigates whether early aspirin use is associated with lower 28-day in-hospital mortality among patients with moderate COVID-19. read more here.
Keywords: aspirin use; hospital mortality; moderate covid; early aspirin ... See more keywords
Early Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.41434
Abstract: Key Points Question How have antiviral agents and monoclonal antibodies for mild to moderate COVID-19 been used in the Veterans Affairs health care system? Findings In this cohort study of 111 717 outpatient US veterans with… read more here.
Keywords: mild moderate; february 2022; moderate covid; anti sars ... See more keywords
Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Neurology"
DOI: 10.1007/s00415-021-10554-1
Abstract: Serum neurofilament light chain (sNfL) is an established biomarker of neuro-axonal damage in multiple neurological disorders. Raised sNfL levels have been reported in adults infected with pandemic coronavirus disease 2019 (COVID-19). Levels in children infected… read more here.
Keywords: antibody; moderate covid; covid; asymptomatic moderate ... See more keywords
31 Emergency Department-Based Monoclonal Antibody Therapy for Patients With Mild to Moderate COVID-19
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Emergency Medicine"
DOI: 10.1016/j.annemergmed.2021.07.032
Abstract: Study Objective: Monoclonal antibody therapy (MOAB) has recently emerged as a treatment for mild to moderate COVID-19, potentially preventing those with underlying conditions from progressing to severe illness and hospitalization. While MOAB administration has commonly… read more here.
Keywords: medicine; treatment; moderate covid; emergency ... See more keywords
Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Infectious Diseases"
DOI: 10.1016/j.ijid.2020.07.078
Abstract: Abstract Aim The aim of the study was to evaluate the safety and efficacy profile of low-dose tocilizumab (TCZ) administered subcutaneously to patients with moderate COVID-19 pneumonia and hyperinflammation to prevent disease progression. Methods We… read more here.
Keywords: hyperinflammation; low dose; moderate covid; patients moderate ... See more keywords
High prevalence of occult thrombosis in cases of mild/moderate COVID-19
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Infectious Diseases"
DOI: 10.1016/j.ijid.2020.12.042
Abstract: Background and purpose More and more reports had observed the thrombosis in severe COVID-19 cases. The aim of this study was to evaluate the incidence of thromboembolism in mild/ moderate COVID-19. All of the patients… read more here.
Keywords: covid pneumonia; high prevalence; moderate covid; covid ... See more keywords
Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Infectious Diseases"
DOI: 10.1016/j.ijid.2021.03.015
Abstract: Objective To evaluate the efficacy and safety of pegylated interferon alfa-2b (PEG IFN-α2b) along with the standard of care (SOC) in subjects with moderate COVID-19. Methods In this phase 2, randomized, open-label study, adult subjects… read more here.
Keywords: ifn plus; moderate covid; plus soc; day ... See more keywords
Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19
Sign Up to like & getrecommendations! Published in 2021 at "Nature Communications"
DOI: 10.1038/s41467-021-25030-7
Abstract: In COVID-19, immune responses are key in determining disease severity. However, cellular mechanisms at the onset of inflammatory lung injury in SARS-CoV-2 infection, particularly involving endothelial cells, remain ill-defined. Using Syrian hamsters as a model… read more here.
Keywords: analysis; infection; moderate covid; syrian hamsters ... See more keywords
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19
Sign Up to like & getrecommendations! Published in 2022 at "Scientific Reports"
DOI: 10.1038/s41598-022-09741-5
Abstract: SARS-CoV-2 is still a health problem worldwide despite the availability of vaccines. Therefore, there is a need for effective and safe antiviral. SARS-CoV-2 and HCV necessitate RNA-dependent RNA polymerase (RdRp) for replication; therefore, it has… read more here.
Keywords: sof vel; treatment; moderate covid; mild moderate ... See more keywords
Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Perinatology"
DOI: 10.1055/s-0042-1753488
Abstract: Abstract Objective The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19). Study Design We report 12 cases of unvaccinated pregnant patients with mild-to-moderate… read more here.
Keywords: mild moderate; disease; casirivimab imdevimab; moderate covid ... See more keywords
VV116 as a potential treatment for COVID-19
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2023.2193668
Abstract: ABSTRACT Introduction VV116 is a chemically-modified version of the antiviral remdesivir with oral bioavailability and potent activity against SARS-CoV-2. Areas Covered The optimal treatment of standard-risk outpatients who develop mild-to-moderate COVID-19 is controversial. While several… read more here.
Keywords: mild moderate; covid; moderate covid; covid vv116 ... See more keywords